ATE329619T1 - Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden - Google Patents

Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden

Info

Publication number
ATE329619T1
ATE329619T1 AT99970328T AT99970328T ATE329619T1 AT E329619 T1 ATE329619 T1 AT E329619T1 AT 99970328 T AT99970328 T AT 99970328T AT 99970328 T AT99970328 T AT 99970328T AT E329619 T1 ATE329619 T1 AT E329619T1
Authority
AT
Austria
Prior art keywords
reperfusion injury
treatment
ischemic reperfusion
spla2 inhibitors
spla2
Prior art date
Application number
AT99970328T
Other languages
English (en)
Inventor
Satoru Todo
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of ATE329619T1 publication Critical patent/ATE329619T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heat Treatment Of Articles (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99970328T 1998-10-14 1999-10-07 Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden ATE329619T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29242398 1998-10-14

Publications (1)

Publication Number Publication Date
ATE329619T1 true ATE329619T1 (de) 2006-07-15

Family

ID=17781604

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99970328T ATE329619T1 (de) 1998-10-14 1999-10-07 Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden

Country Status (7)

Country Link
US (1) US7098237B1 (de)
EP (1) EP1157704B1 (de)
AT (1) ATE329619T1 (de)
AU (1) AU6004799A (de)
CA (1) CA2346334A1 (de)
DE (1) DE69931963D1 (de)
WO (1) WO2000021563A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014378A1 (fr) * 1999-08-23 2001-03-01 Shionogi & Co., Ltd. DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
US7026318B2 (en) * 2000-06-29 2006-04-11 Shionogi & Co., Ltd. Compounds exhibiting X-type sPLA2 inhibiting effect
TWI314457B (de) * 2001-03-19 2009-09-11 Shionogi & Co
DE60205265T2 (de) 2001-09-13 2006-03-30 Synta Pharmaceuticals Corporation, Lexington 1-glyoxylamidindolizine zur behandlung von krebs
JP2005504790A (ja) 2001-09-13 2005-02-17 シンタ ファーマスーティカルズ コーポレイション 癌を治療するための３−グリオキシリルアミドインドール
US20060030620A1 (en) * 2004-08-04 2006-02-09 Chia-Yu Chang Method for treating and/or preventing ischemia/reperfusion injury
JP2009517341A (ja) * 2005-11-03 2009-04-30 イリプサ， インコーポレイテッド Ｃ４−アミド置換基を有するインドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
KR20110103428A (ko) * 2008-12-19 2011-09-20 안테라 파마슈티칼즈, 인크. 분비성 포스포리파제 Ａ２ （ｓＰＬＡ２） 억제제 또는 ｓＰＬＡ２ 억제제 조합 치료요법을 이용한 주요 유해 심장 사건 및 급성 관상동맥 증후군의 치료
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
WO2012027579A1 (en) * 2010-08-26 2012-03-01 Concert Pharmaceuticals, Inc. Synthetic triterpenoid derivatives
AU2018260927B1 (en) * 2018-05-25 2019-02-21 Graham Sherard Baldwin Methods and compositions for inhibiting a noxious insult

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
JPH07285866A (ja) * 1994-02-22 1995-10-31 Eisai Co Ltd 臓器障害予防・治療・改善剤
TW383302B (en) 1994-04-01 2000-03-01 Lilly Co Eli 1H-indole-3-glyoxylamide sPLA2 inhibitors
BR9508298A (pt) * 1994-07-21 1998-11-03 Shionogi & Co Inibidores de indolizina de spla2
US6214876B1 (en) * 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US5648331A (en) * 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
AU1149797A (en) * 1995-12-13 1997-07-03 Eli Lilly And Company Naphthyl glyoxamides as spla2 inhibitors
CA2240395A1 (en) * 1995-12-13 1997-06-19 David Kent Herron Naphthyl acetamides as spla2 inhibitors
WO1998018464A1 (en) * 1996-10-30 1998-05-07 Eli Lilly And Company Substituted tricyclics
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
US5916922A (en) * 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
US5747590A (en) * 1996-12-04 1998-05-05 E. I. Du Pont De Nemours And Company Acrylic-melamine-functionalized oligomer coating composition
ID18983A (id) * 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) * 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
WO1998047507A1 (en) * 1997-04-24 1998-10-29 Shionogi & Co., Ltd. Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
HUP0102981A3 (en) * 1998-03-31 2002-10-28 Shionogi & Co Pyrrolo[1,2-a]pyrazine derivatives and pharmaceutical compositions thereof
EP1085021A4 (de) 1998-05-21 2003-01-08 Shionogi & Co PYRROLO[1,2-B]PYRIDAZIN-DERIVATE MIT sPLA 2? HEMMENDEM EFFEKT

Also Published As

Publication number Publication date
EP1157704B1 (de) 2006-06-14
EP1157704A1 (de) 2001-11-28
WO2000021563A1 (fr) 2000-04-20
AU6004799A (en) 2000-05-01
CA2346334A1 (en) 2000-04-20
DE69931963D1 (de) 2006-07-27
EP1157704A4 (de) 2004-02-25
US7098237B1 (en) 2006-08-29

Similar Documents

Publication Publication Date Title
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE60011570D1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
BR0113161A (pt) Arilóxi piperidinas não imidazóis
ATE329619T1 (de) Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
ATE254458T1 (de) Antibiotische zusammensetzungen zur behandlung des auges
NO20005237L (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
ATE271385T1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
DK1273299T3 (da) Minoxidilinindeholdende praparater
DE69936890D1 (de) Vorrichtung zur Behandlung von Ischämie
DE60013266D1 (de) Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
DE60009665D1 (de) Zusammensetzungen zur behandlung von entzündungsreaktionen
FI935777A0 (fi) Inhibitorer foer HIV-proteas anvaendbara vid behandling av AIDS
DE60029242D1 (de) Arzneien zur begleitenden behandlung von glaukomen
ATE288303T1 (de) Östrogen agonist-antagonist und testosteron enthaltende zusammensetzung zur behandlung abnehmender testosteronspiegel
ATE428425T1 (de) Spla2-inhibitoren zur behandlung von arteriosklerose
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ES2096874T3 (es) Inhibidor de la proteasa de hiv util para el tratamiento del sida.
ATE263566T1 (de) Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom
DE60203026D1 (de) Sulfonylpyridazinone Derivate zur Behandlung von ischämischem Gewebeschaden
WO2003041640A3 (en) METHODS FOR TREATING ISCHEMIC REPERFUSION INJURY USING IkB KINASE-BETA INHIBITORS
DE60000658T2 (de) Zusammensetzung zur behandlung von psoriasis
ATE390920T1 (de) Lipase inhibitoren zur behandlung von dyspepsia
ATE271384T1 (de) Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
DE69808607T2 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties